Printer Friendly

ALPHA 1 BIOMEDICALS APPOINTS MARTIN ROSE SENIOR VICE PRESIDENT, CLINICAL AND REGULATORY AFFAIRS

 BETHESDA, Md., July 19 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) today announced the appointment of Martin Rose, M.D., J.D., as senior vice president, clinical and regulatory affairs. His principal assignment will be to guide the company's lead product, Thymosin alpha 1, now in Phase III clinical trials for the treatment of chronic hepatitis B, through the regulatory approval process. Previously, Dr. Rose was senior director, government affairs, of Genentech, Inc.
 "We are delighted to have Dr. Rose join our company at this important time," said Vincent F. Simmon, Ph.D., president and CEO of Alpha 1. "He brings a wealth of FDA regulatory experience from his years at the agency where he was responsible for review of many important cardiovascular agents. In addition, his legal and public policy background will be of immeasurable value to Alpha 1 Biomedicals."
 Dr. Rose received his M.D. degree from the University of California, San Francisco, and his J.D. degree from the University of California, Berkeley. Dr. Rose did an internship and medical residency at Saint Mary's Hospital, San Francisco, and was a fellow in endocrinology at the San Francisco Veterans Administration Hospital. From 1981 to 1983, Dr. Rose was a practicing attorney representing pharmaceutical clients at Arnold & Porter in Washington. From 1983 to 1985, and from 1986 to 1988, Dr. Rose was medical officer and group leader in the division of cardio-renal drug products at the Food and Drug Administration, in Rockville, Md. From 1985 to 1986 he was chief medical officer, office of medical applications of research, in the office of the director at NIH in Bethesda. He joined the government affairs office of Genentech in 1988.
 Alpha 1 Biomedicals, Inc. is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 -0- 7/19/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, 301-564-4400, or Harold Silverman of InterScience Communications, 202-973-0362/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU: PER

WB-MP -- NY089 -- 3266 07/19/93 17:07 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:374
Previous Article:TEXAS-NEW MEXICO POWER COMPANY FILES REGISTRATION STATEMENT FOR DEBT OFFERINGS
Next Article:REGENT BANCSHARES ANNOUNCES RESULTS
Topics:


Related Articles
ALPHA 1 BIOMEDICALS, INC. APPOINTS FRANK P. MAMARIL AS DIRECTOR OF QUALITY CONTROL
/FOLLOWING IS A REPEAT OF A RELEASE MOVED YESTERDAY/
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
ALPHA 1 BIOMEDICALS NAMES ERNEST R. TYLER VICE PRESIDENT, OPERATIONS
ALPHA 1 BIOMEDICALS, INC. PROMOTES SUZANNE K. BECKNER TO VICE PRESIDENT, DEVELOPMENT
ALPHA 1 BI0MEDICALS, INC. APPOINTS MICHAEL L. BERMAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
TRANSCEND THERAPEUTICS, INC. APPOINTS JOHN J. WHALEN, M.D. AS SENIOR VP AND CHIEF SCIENTIFIC OFFICER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters